Role of Dexamethasone in Meningitis

Emad uddin Siddiqui and Ghazala Irfan Qazi
Aga Khan University Hospital
Pakistan

1. Introduction

The inflammatory cascade in acute bacterial meningitis leads to tissue damage and exudates accumulation especially in H. influenza, pneumococcal meningitis and in tuberculous meningitis. The administered antibiotics will also exaggerate the formation of inflammatory exudates from tissue destruction and endotoxins from bacterial lysis, resulting in edema formation. Accumulation of these inflammatory substrates, neutrophils and edema ultimately results in ischemia and pressure effect on neurons and nerve fibers with worsening of neurological signs and symptoms.

Despite the effective antibiotic therapies, bacterial meningitis still has considerable morbidity and mortality in both adult and pediatric population. (Brouwer MC et al., 2010).

Other than the definitive treatment with appropriate antibiotics, supportive and adjuvant therapy has its own characteristic role in the improved outcome of disease. Evidence from experimental models also support the role of adjuvant therapy like, early administration of glucocorticoids in selective cases of pyogenic meningitis, however most modalities investigated so far have not been sufficient for their routine use in the management of all cases of meningitis.

2. Pathophysiology

According to Monro-Kellie doctrine (Morki B, 2008), if there is an increasing size of one constituent or a mass within the cranial vault, the pressure will be shared by either brain, arterial and venous blood flow and/or the CSF. Similarly, if there is trauma or inflammation to brain parenchyma or meninges, exudates will accumulate with oedema, and edematous and inflamed brain causes either partial or complete obstruction of CSF flow which may result in hydrocephalus. Edematous and inflamed brain reduces the venous blood flow from cranial vault, leading to venous congestion and edema, on the other hand, it also hampered arterial blood supply and hence reduce brain perfusion, and oxygenation which may further aggravate hypoxic inflammation and hence worsening of edema, thereby further increasing intracranial venous congestion and pressure, consequently compromising the brain parenchyma results in different clinical presentation like altered mental status.
Fig. 1. Monro-Kellie hypothesis: Increase in volume (mass effect) of cranial constituents (blood, CSF, and brain tissue) must be compensated by a decrease in volume of another.

Fig. 2. Monro-Kellie hypothesis in case of increase in intracranial pressure and hydrocephalus, compromising arterial and venous blood and compressed brain parenchyma and CSF.

3. Role of anti-inflammatory agents

There are a wide spectrum of complications associated with meningitis, these may be neurological and non-neurological (systemic). Systemic complications relate with bacteremia and related toxins, which ranges from sepsis to septic shock, disseminated intravascular coagulation, respiratory distress syndrome and respiratory arrest, while prolonged fever, vasomotor collapse, pericardial effusion, arthritis, hypothalamic and other endocrine dysfunction including hyponatremia and bilateral adrenal hemorrhage are also not uncommon. Anemia may also manifest as a part of meningitis.
Several anti-inflammatory agents have been studied in reducing the inflammatory exudates in animal models of pyogenic and other types of meningitis. Indomethacin, platelet factor inhibitors, and pentoxifylline, recombinant protein C, intravenous immunoglobulin, and monoclonal antibodies, have been evaluated for their isolated and combined anti-inflammatory properties in reducing CSF inflammation and edema, but none of them have evident promising results. (Singhi P et al., 2008)

Though the role of glucocorticoids in systemic complications of meningitis is not discussed in the literature as extensively as it has been described for neurological outcomes, especially in reducing the incidence of hearing loss and other acute or chronic neurological sequelae, on the contrary, use of glucocorticoids did not reduce overall mortality in most cases of meningitis. Cochrane review data supports its use in patients with bacterial meningitis in high-income countries, but results were not found to be beneficial from low-income countries. (Daoud AS et al., 1999).

Bacterial immunogenicity, host immunity and response, timing and efficacy of antibiotics and steroids used, and susceptibility of the organism all account for the consequences in low-income countries. The adjunctive benefit of corticosteroids during treatment of meningitis caused by other organisms (viral, fungal, and parasitic) is unknown.

4. Role of steroids in meningitis

With its unique anti-inflammatory and immune suppressive properties, efficacy of this drug has been extensively studied in different types of meningitis. Adjuvant therapy of glucocorticoids like dexamethasone is useful in both adult and pediatric meningitis and tuberculous meningitis as evident from experimental studies and vast growing clinical data. (Friedland IR et al., 1994)

Steroid limits the production of inflammatory mediators like IL-1, IL-6 and TNF and exudates and help in reduction of edema, resulting in the decrease cerebral pressure and hence improve CSF flow within the cistern thus helps in stabilizing the blood brain barrier (BBB), this in turn leads to improvement of neurological symptoms. (Karen & Tyler 2008).

Dexamethasone also inhibits the production of TNF by macrophages and microglia, but only if it is administered before these cells are activated by endotoxin. A meta-analysis conducted in 2010 on the role of dexamethasone in pediatric meningitis has shown that dexamethasone did not improve overall mortality; however, it can reduce severe hearing loss in children. (Brouwer MC et al., 2010). However, the etiological agents, nutritional status, prior immunity and immunization, and demography play an important role in the outcome of such meningitis.

Most experts had consensus on the beneficial role of steroids with its maximum benefits when it is used at least one hour prior to recommended antibiotics therapy. (King, 1994; Pickering, 2009). Regarding H. Influenzae meningitis in children older than six weeks, the use of steroid prior to antibiotics is recommended by the American Academy of Pediatrics and as described in Infectious Diseases Society of America (IDSA) guidelines 2004. (Tunkel AR et al., 2004). In H. Influenzae meningitis steroids significantly reduce the risk of sensorineural hearing loss, while other experts' belief that outcome of meningitis is not dependent on steroids when it was given. Dexamethasone also did not help in ameliorating the other neurologic consequences especially in children. (Brouwer MC et al., 2010).
Meningitis

Beneficial role of dexamethasone in neonatal meningitis has not been evidenced from the literature. It is not indicated in bacterial meningitis in children younger than six weeks, as it does not show promising results in different past studies. Steroids are also not advised as adjuvant therapy in patients with congenital or acquired CNS anomalies. (Daoud AS et al., 1999).

The severity of illness at the time of presentation may appear to play a prominent role in outcome than just administration of adjuvant therapy with dexamethasone. (Peltola H et al., 2010). On the other hand, dexamethasone may also mask the clinical presentation of meningitis, or any of its associated sequelae like abscess, empyema, subdural collection, tuberculous meningitis, or resistant meningitis. Routine administration of dexamethasone is also not recommended in developing countries as most patients get their first few doses of antibiotics before the diagnosis of meningitis. Still, dexamethasone has a role in reducing the inflammatory exudates if given with or soon after the initial antibiotics preferably within one hour, but this time interval is not clearly defined in literature. (King SM et al., 1994).

With the advent of effective immunization against H. Influenzae globally, Streptococcal Pneumoniae is becoming the common organism causing meningitis. Resistance of S. pneumoniae to cephalosporins group is also evidently increasing from literature. Widespread use of susceptible vancomycin against these resistant species of S. pneumoniae is increasing. At the same time, studies had shown an increasing number of therapeutic failures when dexamethasone is combined with vancomycin and various other antibiotics like rifampicin and cephalosporin, etc. Steroids may reduce the penetration of these antibiotics in CSF or it may lead to a decrease level of some antibiotic (e.g., vancomycin, ceftriaxone, and rifampin), mechanism is not clear. (Friedland, 1994; Moellering, 1984).

Fig. 3. CT scan brain showing low attenuated areas and increased enhancements with hydrocephalus in patient with pneumococcal meningitis.
Role of Dexamethasone in Meningitis

Dexamethasone in case of pneumococcal meningitis should be used after considering the risks and benefits. In adults with pneumococcal meningitis, dexamethasone has shown to have clinical benefits in terms of neurological outcomes, but in children its use is controversial in pneumococcal meningitis. On the other hand, few experts recommend that it should be used in all cases of confirmed or suspected pneumococcal meningitis even if they are previously vaccinated, while others focused on the risk and benefits. However, experts' consensus that steroids are only effective in reducing hearing loss if given before antibiotics. (Pickering 2009).

In patients with hypoplasia, sickle cell disease and complement and immune deficiency, corticosteroids should be used cautiously. Thus, controversies for its use in pneumococcal meningitis still persist. Dexamethasone is also not recommended in patients with aseptic meningitis, nonbacterial, or meningitis with gram-negative enteric bacteria. In such cases, dexamethasone if started before should be discontinued as soon as a diagnosis of nonbacterial or gram-negative enteric meningitis is confirmed. (Tunkel AR et al., 2004).

Randomized controlled trials from low income countries with steroid therapy in tuberculosis meningitis for initial 6-8 weeks of antitubercular treatment were found to have significantly reduced mortality in patients who present with stage I disease; there was also reduced mortality noticed in patients who present with stage II disease. (Thwaites, GE. et al., 2008). However, there was no significant long-term reduction in the residual neurologic deficits and disability among survivors. Prednisone as compared to dexamethasone is associated with a significant reduction in mortality in children with tuberculous meningitis compared to adults. (Thwaites, GE. et al., 2008).

5. Doses of dexamethasone in meningitis

In case of pyogenic meningitis, dexamethasone should be used at 0.15 mg/kg per dose (10 mg intravenously in adults) every six hours for two to four days (Tunkel AR et al., 2004). Two days of dexamethasone appear to be as effective as and less toxic than longer courses. (Syrogiannopolus GA et al., 1994)

Steroids should be started at presentation or before or with the commencement of antitubercular therapy. Dexamethasone, dose of 8 mg/day for children weighing <25 kg, 12 mg/day for adults and children >25 kg, for 3 weeks, and then tapered off gradually over the following 3 to 4 weeks. Prednisone, dose of 2 to 4 mg/kg/day for children and 60 mg/day for adults, for 3 weeks, then tapered off gradually over the following 3 weeks.

6. Complication of dexamethasone

Problems related with the glucocorticoids use are usually associated with its prolonged duration. There may be complexity in clinical assessment and response to therapy, gastrointestinal bleeding, secondary fever, hypertension, hyperglycemia, leukocytosis, etc. It may also impair antibiotic penetration into the cerebrospinal fluid (CSF) that can lead to therapeutic failure, particularly in areas with increasing rates of penicillin-resistant S. pneumoniae. (Thomas R et al., 1999).

Corticosteroids do not reverse CNS damage that has already resulted from the pathophysiologic consequences of bacterial meningitis (e.g., cerebral edema and increased pressure).
Meningitis

However, even in children with bacterial meningitis in the developing world, use of adjunctive dexamethasone should be considered, because no adverse effects were attributable to its administration in this trial and its use may benefit some of the children with this devastating disorder. (Mongelluzo J et al., 2008)

7. Dexamethasone in adult meningitis

Clinical trials of corticosteroids (dexamethasone) as adjuvant therapy have been conducted in different centers all over the world with inconsistent results. However studies shown that corticosteroids significantly reduced severe hearing loss and other neurologic sequel, while on other hand, it is also helpful in reducing the overall mortality. Meta analysis using dexamethasone in adult meningitis demonstrates favorable outcomes in terms of both morbidity and mortality especially in cases of pneumococcal meningitis. It also reduces mortality in adult onset streptococcal pneumoae meningitis. (Daniel J S et al., 2010). Dexamethasone is also associated with reduce rate of acute neurological and hearing defect, however there was no difference in long term neurological sequelae, (Brouwer MC et al., 2010) although some experts recommend to discontinue dexamethasone if S. pneumonia was not found in the CSF culture, but others still recommend the use of adjunctive dexamethasone regardless of microbial etiology in conjunction with the first dose of antimicrobial therapy. (de Gans & Van de, 2002)

8. Dexamethasone in pediatric meningitis

The role of dexamethasone use in cases of pediatric meningitis is more controversial, it must be individualized according to the organism especially in case of H. influnzae and pneumococcal meningitis. Even though, a better outcome can only be attained if dexamethasone is use before or at the same time of first dose of antibiotics. (Tunkel AR et al., 2004). Routine use of dexamethasone in pediatric population is not recommended, potential risk and benefits must be taken into account as it may not reverse neuronal damage that has already resulted from the pathophysiologic consequences of bacterial meningitis.

However, even in children with bacterial meningitis in the developing world, use of adjunctive dexamethasone should be considered, because no adverse effects were attributable to its administration in this trial and its use may benefit some of the children with this devastating disorder.

9. Dexamethasone in neonatal meningitis

The administration of dexamethasone did not significantly affect mortality or neurologic outcome in small children up to two years of age, hence it is not currently recommended. (Daoud AS et al., 1999).

10. Acknowledgment

I would like to thanks Ms Uzma Siddiqui who gave me enormous moral assistant in writing this book chapter. I am also thankful to Saiufi Islam and Zainul Islam for their kind support.
11. References

Brouwer, MC. Mcintyre, P. de-G ans, J. Prasad, K. Van-de-Beek, D. (2010). Corticosteroids for acute bacterial meningitis. Cochrane database systemic review 2010, Sept 08 ;( 09). CD004405.

Daniel, J S. Stephen, B C. Anna, R T. (October 4, 2010). Dexamethasone to prevent neurologic complications of bacterial meningitis in adults. Up to date on line. Version 18.3: September 2010. Accessed on 12/06/2011. http://www.uptodate.com/contents/dexamethasone-to-prevent-neurologic-complications-of-bacterial-meningitis-in-adults?source=search_result&selectedTitle=1%7E150

Daoud, AS. Batieha, A. Al-Sheyyab, M. (1999). Lack of effectiveness of dexamethasone in neonatal bacterial meningitis. Eur J Pediatr 1999; 158:230-33.

De-Gans, J. Van-de-Beek, D. (2002). Dexamethasone in adults with bacterial meningitis. N Engl J Med 2002; 347:1549-1556.

Friedland, IR. Paris, M. Shelton, S. McCracken, GH. (1994). Time-kill studies of antibiotic combinations against penicillin-resistant and susceptible Streptococcus pneumoniae. J Antimicrob Chemother 1994; 34:231.

King, SM. Law, B. Langley, JM. (1994). Dexamethasone therapy for bacterial meningitis: Better never than late? Can J Infect Dis 1994; 5:210

Mace, SE. (2008). Acute Bacterial Meningitis. Emerg Med Clin N Am; 26(2) :2008 281–317

Moellering, RC. (1984). Pharmacokinetics of vancomycin. J Antimicrob Chemother 1984; 14 Suppl D: 43.

Mokri, B. The Monro–Kellie hypothesis. Applications in CSF volume depletion. Neurology 2001;56:1746–1748

Mongelluzo, J. Mohamad, Z. Ten-Have, TR. Shah, SS. (2008). Corticosteroids and mortality in children with bacterial meningitis. JAMA 2008; 299:2048-2055.

Odio, CM. Faingezicht, I. Paris, M. Nassar, M. Baldassano, A. Rogers, J. Saez-Lorenz, X. Olsen, KD. Mccracken, GH. (1991). The beneficial effects of early dexamethasone administration in infants and children with bacterial meningitis. N Engl J Med 1991; 30: 324 (22):1525-31

Peltola, H. Roine, I. Fernández, J. Gonzalez Mata, A. Zavala, I. Avala, SG. Mata, AG. Arbo, A. Bolonga, R. Mino, G. Goyo, J. Lopez, E. deAndrade, SD. Sarna, S. (2007). Adjuvant glycerol and/or dexamethasone to improve the outcomes of childhood bacterial meningitis: a prospective, randomized, double-blind, placebo-controlled trial. Clin Infect Dis 2007, 15; 45(10):1277-86.

Pelton, SI. Yogev, R. (2005). Improving the outcome of pneumococcal meningitis. Arch Dis Child 2005; 90(4):333–4.

Pickering, LK. (2009). Summaries of infectious disease. Haemophilus influenzae infections: Page 314-321. Red Book: Report of the Committee on Infectious Diseases, 28th ed, American Academy of Pediatri cs, Elk Grove Village, IL. www.intechopen.com
Meningitis is a medical emergency requiring a rapid diagnosis and an immediate transfer to an institution supplied with appropriate antibiotic and supportive measures. This book aims to provide general practitioners, paediatricians, and specialist physicians with an essential text written in an accessible language, and also to highlight the differences in pathogenesis and causative agents of meningitis in the developed and the developing world.

How to reference

In order to correctly reference this scholarly work, feel free to copy and paste the following:

Emad uddin Siddiqui and Ghazala Irfan Qazi (2012). Role of Dexamethasone in Meningitis, Meningitis, Prof. George Wireko-Brobby (Ed.), ISBN: 978-953-51-0383-7, InTech, Available from: http://www.intechopen.com/books/meningitis/role-of-dexamethasone-in-meningitis
